Financial Review: Jupiter Neurosciences (NASDAQ:JUNS) vs. CERo Therapeutics (NASDAQ:CERO)

CERo Therapeutics (NASDAQ:CERO) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability and dividends.

Insider and Institutional Ownership

29.6% of CERo Therapeutics shares are held by institutional investors. 0.4% of CERo Therapeutics shares are held by company insiders. Comparatively, 50.8% of Jupiter Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

CERo Therapeutics has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500. Comparatively, Jupiter Neurosciences has a beta of 1.71, meaning that its stock price is 71% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and target prices for CERo Therapeutics and Jupiter Neurosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1	2	0	0	1.67
Jupiter Neurosciences	1	0	0	0	1.00

CERo Therapeutics currently has a consensus target price of $30.00, suggesting a potential upside of 275,129.36%. Given CERo Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe CERo Therapeutics is more favorable than Jupiter Neurosciences.

Profitability

This table compares CERo Therapeutics and Jupiter Neurosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%

Valuation & Earnings

This table compares CERo Therapeutics and Jupiter Neurosciences”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30 million	($71.01)	0.00
Jupiter Neurosciences	$40,448.00	213.48	-$8.65 million	($0.27)	-0.88

CERo Therapeutics has higher earnings, but lower revenue than Jupiter Neurosciences. Jupiter Neurosciences is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

CERo Therapeutics beats Jupiter Neurosciences on 7 of the 11 factors compared between the two stocks.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.